GET DAILY SIGNALSLeonaBio (LONA) Q3 2026 Preview: Pipeline Updates and Cash Runway Take Center Stage
Key Takeaways
- LeonaBio (LONA) is a pre-revenue, clinical-stage biopharmaceutical company, so its third-quarter 2026 report will center on net loss per share, research and development (R&D) spending, and cash runway rather than sales.
- Wall Street consensus points to a third-quarter net loss of roughly $0.62 to $0.69 per share, with reported revenue expected at $0.
- In the prior quarter (Q2 2026), LeonaBio posted a net loss of about $19 million, or $0.80 per share, as it continued funding its lead drug programs.
- Investors will focus on progress for lasofoxifene in the Phase 3 ELAINE-3 breast cancer trial and ATH-1105 in ALS (amyotrophic lateral sclerosis, a progressive neurological disease).
- Management has indicated its cash position should support operations into 2028, making any updated spending or financing commentary a key watch item.
Putting the Quarter in Context
LeonaBio (LONA), formerly Athira Pharma, rebranded in January 2026 after securing global rights to lasofoxifene from Sermonix Pharmaceuticals and completing a roughly $90 million private placement. As a clinical-stage company with no approved products, it generates no revenue, so quarterly results function as a report card on spending discipline and trial execution. The third-quarter 2026 update arrives at a pivotal moment: lasofoxifene's Phase 3 ELAINE-3 trial is more than 50% enrolled with data expected in mid-2027, while ATH-1105 is preparing to advance in ALS. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors will read the numbers for clues on cash burn, milestone payments, and whether the stated runway into 2028 remains intact.
What Analysts Are Modeling
Because LeonaBio (LONA) has no commercial revenue, analysts model the quarter primarily on the bottom line. Consensus expectations call for a third-quarter net loss in the range of roughly $0.62 to $0.69 per share, with revenue forecast at $0. For context, the company reported a net loss of about $19 million ($0.80 per share) in Q2 2026 and a larger loss of roughly $32.9 million ($1.73 per share) in Q1 2026 — the latter inflated by a non-cash charge tied to a change in the fair value of a pre-funded warrant. The first-quarter report also highlighted a jump in R&D expense as spending on the newly in-licensed lasofoxifene program ramped up. Heading into this report, investors are watching whether that spending trajectory continues and how it affects the stated cash runway into 2028.
Market Reaction and Sentiment
LeonaBio’s (LONA) shares have historically been volatile around earnings, reflecting its status as a clinical-stage biotech whose valuation is driven more by pipeline milestones than by quarterly profit-and-loss results. Past earnings reactions have ranged from modest gains to single-digit declines, and the stock has experienced a notable post-earnings drift following its August 2026 report. Heading into the third-quarter release, sentiment is largely tied to trial timelines and cash-burn trends rather than earnings surprises in the traditional sense. Key risk factors include the potential for higher-than-expected R&D spending, updated commentary on capital-raising constraints, and any shifts in the timing of clinical data readouts.
Key Catalysts to Watch Going Forward
The most important catalyst on LeonaBio’s (LONA) horizon is lasofoxifene, a selective estrogen receptor modulator being studied in the Phase 3 ELAINE-3 trial for ESR1-mutated metastatic breast cancer. This ESR1 mutation is associated with resistance to standard endocrine therapy, and the company has said the trial is more than 50% enrolled with topline data expected in mid-2027.
Investors should also watch for progress on ATH-1105, LeonaBio’s oral drug candidate for ALS, as the company prepares to advance it into Phase 2 testing. On the financial side, commentary on the cash runway — which management has said should reach into 2028 — and on research and development expense will be closely monitored.
One additional factor worth noting is the company’s temporary ineligibility to use Form S-3 for registered offerings through December 2026, which limits certain expedited capital-raising options. How management addresses future financing needs, alongside clinical execution, will be central to the outlook following this report.
AI Tools in My Research Workflow
When analyzing clinical-stage names like LeonaBio (LONA), I often rely on Tickeron’s AI Screener to quickly filter peers by sector, market cap, and technical signals. It helps surface comparable opportunities and keeps my pipeline monitoring efficient without replacing deeper fundamental work. This tool has become a regular part of how I cross-check biotech names ahead of events like earnings or trial updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LONA sees MACD Histogram just turned negative
LONA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 38 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LONA as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LONA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for LONA entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LONA's RSI Oscillator exited the oversold zone, 30 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where LONA advanced for three days, in 211 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.217) is normal, around the industry mean (2.788). P/E Ratio (-0.189) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LONA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LONA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement